Jump to Main Content
Functional expression of sodium-glucose transporters in cancer
- Scafoglio, Claudio, Hirayama, Bruce A., Kepe, Vladimir, Liu, Jie, Ghezzi, Chiara, Satyamurthy, Nagichettiar, Moatamed, Neda A., Huang, Jiaoti, Koepsell, Hermann, Barrio, Jorge R., Wright, Ernest M.
- Proceedings of the National Academy of Sciences of the United States of America 2015 v.112 no.30 pp. E4111
- animal models, glucose, glucose transporters, image analysis, neoplasm cells, patients, positron-emission tomography, prostatic neoplasms, viability
- Cancers require high amounts of glucose to grow and survive, and dogma is that uptake is facilitated by passive glucose transporters (GLUTs). We have identified a new mechanism to import glucose into pancreatic and prostate cancer cells, namely active glucose transport mediated by sodium-dependent glucose transporters (SGLTs). This means that the specific radioactive imaging probe for SGLTs, α-methyl-4-deoxy-4-[ ¹⁸F]fluoro- d -glucopyranoside, may be used along with positron-emission tomography to diagnose and stage pancreatic and prostate cancers, tumors in which the GLUT probe 2-[ ¹⁸F]fluoro-2-deoxy- d -glucose has questionable utility. Moreover, we suggest, based on our results in mouse models, that Food and Drug Administration-approved SGLT2 inhibitors may be used to reduce the viability of pancreatic and prostate cancer cells in patients.